DUBLIN--(BUSINESS WIRE)--The "Biosimilar Lymphocyte Modulator Global Market Report 2022: By Drug, By Disease" report has been added to ResearchAndMarkets.com's offering.
The global biosimilar lymphocyte modulator market is expected to grow from $1.16 billion in 2021 to $1.34 billion in 2022 at a compound annual growth rate (CAGR) of 15.4%. The market is expected to reach $2.10 billion in 2026 at a CAGR of 11.8%.
The main types of drugs in biosimilar lymphocyte modulator are campath-1H, natalizumab biosimilar, efalizumab - A1089-anti-CD11A biosimilar, anti-CD38 daratumumab biosimilar, anti-CS1 elotuzumab biosimilar. Campath is a prescription medication used to treat the symptoms of CLL. Campath can be taken on its own or in combination with other drugs. The different diseases include arthritis, diabetes, multiple myeloma, enterocolitis, multiple sclerosis, psoriasis, others
Immunotherapy combined with other cancer treatments is expected to drive the growth of the biosimilar lymphocyte modulators market. The combination of immunotherapies or pairing of immunotherapies with other types of cancer treatments such as chemotherapy or radiation enhances the benefit associated with lymphocyte modulators.
According to a study conducted by the researchers at Washington University School of Medicine in St. Louis, combining two immunotherapy strategies into one can give better results for certain blood cancers such as leukaemia. Evidence suggests that this new approach could be safer with reduced side effects than other cellular immunotherapies such as CAR-T cell. The combination approach, therefore, saves patients' life from a life-threatening reaction of the immune system thereby driving the growth of the lymphocyte modulator market.
The shortage of raw material for lymphocyte modulator drugs is expected to restrict the growth of the biosimilar lymphocyte modulator market. Drug shortages are due to several factors including challenges for acquiring raw materials, manufacturing problems, regulatory issues, business decisions, and numerous disturbances within the supply chain. They adversely affect patient care by causing the replacement of safe and effective therapies with elective medicines, compromising or delaying medical procedures, or causing medication errors.
For instance, in January 2019, the American Society of Haematology, an association comprising of clinical scientists and physicians that provides care to patients in diverse settings, sent a letter to USFDA highlighting the issue of shortage of critical hematologic drugs such as etoposide and methotrexate, which have no alternatives. Mainly the drug etoposide, which is a chemotherapeutic drug, that is a crucial component in treatment regimens designed to be curative for life-threatening conditions including leukaemia and lymphomas. Due to the shortage, some patients have received less effective treatment. Thus, the raw material shortages cause delayed and compromised medical treatments and also results in limiting the growth of the market.
Tumor-Infiltrating Lymphocyte Immunotherapy has been gaining popularity in recent times because of its positive results in anti-cancer treatments. Tumor-infiltrating lymphocytes (TILs) comprise of all lymphocytic cell populaces that have occupied the tumor tissue.
TILs have been depicted in various solid tumors including breast cancer, and are emerging as a significant biomarker in predicting the efficacy and result of treatment. Due to promising results, many companies have started launching TIL technologies. For instance, in January 2020, Lovance Biotherapeutics, a US-based start-up company, has licensed TALEN technology from Cellectis to develop gene-editing tumor-infiltrating lymphocytes (TIL) to treat several cancer indications. Other companies investing in TIL technology are Optera Therapeutics Corp and TILT Biotherapeutics.
Scope
Markets Covered:
1) By Drug: Campath-1H; Natalizumab Biosimilar; Efalizumab - A1089-Anti-CD11a Bisoimilar; Anti-CD38 Daratumumab Biosimilar; Anti-CS1 Elotuzumab Bisoimilar
2) By Disease: Arthritis; Diabetes; Multiple Myeloma; Enterocolitis; Multiple Sclerosis; Psoriasis; Others
Key Topics Covered:
1. Executive Summary
2. Biosimilar Lymphocyte Modulator Market Characteristics
3. Biosimilar Lymphocyte Modulator Market Trends And Strategies
4. Impact Of COVID-19 On Biosimilar Lymphocyte Modulator
5. Biosimilar Lymphocyte Modulator Market Size And Growth
6. Biosimilar Lymphocyte Modulator Market Segmentation
7. Biosimilar Lymphocyte Modulator Market Regional And Country Analysis
8. Asia-Pacific Biosimilar Lymphocyte Modulator Market
9. China Biosimilar Lymphocyte Modulator Market
10. India Biosimilar Lymphocyte Modulator Market
11. Japan Biosimilar Lymphocyte Modulator Market
12. Australia Biosimilar Lymphocyte Modulator Market
13. Indonesia Biosimilar Lymphocyte Modulator Market
14. South Korea Biosimilar Lymphocyte Modulator Market
15. Western Europe Biosimilar Lymphocyte Modulator Market
16. UK Biosimilar Lymphocyte Modulator Market
17. Germany Biosimilar Lymphocyte Modulator Market
18. France Biosimilar Lymphocyte Modulator Market
19. Eastern Europe Biosimilar Lymphocyte Modulator Market
20. Russia Biosimilar Lymphocyte Modulator Market
21. North America Biosimilar Lymphocyte Modulator Market
22. USA Biosimilar Lymphocyte Modulator Market
23. South America Biosimilar Lymphocyte Modulator Market
24. Brazil Biosimilar Lymphocyte Modulator Market
25. Middle East Biosimilar Lymphocyte Modulator Market
26. Africa Biosimilar Lymphocyte Modulator Market
27. Biosimilar Lymphocyte Modulator Market Competitive Landscape And Company Profiles
28. Biosimilar Lymphocyte Modulator Pipeline Analysis
29. Key Mergers And Acquisitions In The Biosimilar Lymphocyte Modulator Market
30. Biosimilar Lymphocyte Modulator Market Future Outlook and Potential Analysis
31. Appendix
Companies Mentioned
- Pfizer
- Biogen
- Genentech
- Novartis
- Celltrion
For more information about this report visit https://www.researchandmarkets.com/r/8ys3zr
